Fingerprint
Dive into the research topics of 'Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Who Benefits the Most From Adjuvant Durvalumab After Chemoradiotherapy for Non-small Cell Lung Cancer? An Exploratory Analysis
Nitin Ohri, Balazs Halmos, William R. Bodner, Haiying Cheng, Madhur K. Garg, Rasim Gucalp, Chandan Guha
Research output: Contribution to journal › Article › peer-review
11
Scopus
citations